Fox Chase Cancer Center News

The National Accreditation Program for Breast Centers (NAPBC) has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

Researchers at Fox Chase Cancer Center received a prestigious Director’s Discretionary Allocation Award from Argonne National Laboratory, part of the U.S. Department of Energy. The allocation supports the Melanoma-Immune Checkpoint Blockade project (ICB), a Fox Chase initiative aimed at advancing research in melanoma immunotherapy.

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts, a phenomenon they describe as “cell-in-cell.”

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

Fox Chase Cancer Center’s Anthony Villano, MD, FACS, Assistant Professor in the Department of Surgery, and Jeffrey Farma, MD, FACS, Chair of the Department of Surgery, are editors of a new textbook aimed at introducing surgical oncology trainees to important career concepts.

Fox Chase Cancer Center has once again been recognized among the nation’s leading institutions for cancer care in the 2025–2026 U.S. News & World Report Best Hospitals rankings.

Using a novel method to analyze tumor growth rates, researchers at Fox Chase Cancer Center have provided the most in-depth assessment to date of how fast breast cancers grow in patients and how surgical delays may affect breast cancer staging, which measures the extent of cancer spread in the body. The newly published study offers new insight into how tumors progress in the time between diagnosis and surgery.

MBCure, a nonprofit focused on metastatic breast cancer (MBC) research, awareness, education, and access efforts, is launching the MBCure Research Consortium with three of the world’s leading cancer institutions: Fox Chase Cancer Center, Penn Medicine’s Abramson Cancer Center, and Memorial Sloan Kettering Cancer Center (MSK).